Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person's chance ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

Users of GLP-1 drugs in the US cut their grocery spending by an average of 5.5% in the six months after taking the medication, a study shows.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...

Attorney General Kwame Raoul is warning Illinois residents seeking GLP-1 medications – Ozempic, Wegovy, Mounjaro, Zepbound ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...